Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7849307 | 0.93 | ALDH1A1 (0.50) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL7848626 | 0.91 | ALDH1A1 (0.48) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL2466528 | 0.83 | ALDH1A1 (0.62) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL15218938 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL961555 | 0.78 | ALDH1A1 (0.47) | ALDH1A1POLBKMT2ASMN1; SMN2RAB9A | |
| SCHEMBL11349289 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL2048930 | 0.76 | ALDH1A1 (0.57) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL7081345 | 0.75 | MAPT (0.47) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL7278926 | 0.75 | ALDH1A1 (0.60) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL367990 | 0.75 | MAPT (0.47) | ALDH1A1POLBKMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| EP-1286998-B1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| EP-1286998-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001081350-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-01 | — | — | WO | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | ALDH1A1 3134/4885KDM4E 1730/4885POLB 984/4885 |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | ALDH1A1 2884/4885KDM4E 1829/4885POLB 1454/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | ALDH1A1 1293/4885KDM4E 1696/4885POLB 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.